Background Randomized clinical trials comparing the efficacy and safety of direct oral
anticoagulants (DOAC) with vitamin K antagonist (VKA) or low molecular weight heparin …

Introduction: Limited data exists on the safety and efficacy of direct‐acting oral
anticoagulants (DOAC) use in morbidly obese patients with venous thromboembolism …

Background Direct oral anticoagulants'(DOAC) pharmacokinetics are affected by obesity.
Their efficacy and safety in obesity (BMI≥ 30 kg/m 2) and morbid obesity (BMI≥ 40 kg/m 2) …

In 2016, the International Society on Thrombosis and Haemostasis (ISTH) published
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …

Abstract Purpose of Review The purpose of this review is to examine the safety and
effectiveness of direct oral anticoagulants and provide recommendations for the treatment of …

Obesity plays an essential role in the safety of pharmacologic drugs. There is paucity of data
for direct oral anticoagulants (DOACs) in the obese, despite these agents becoming more …

Background: Consensus statements have recommended against the use of direct oral
anticoagulants (DOACs) in venous thromboembolism (VTE) for patients≥ 120 kg and≥ 40 …

Study Objective Studies on the use of direct oral anticoagulants (DOACs) in obese patients
are limited. Current guidelines advise against DOAC use in patients with a body weight …

Purpose To review the literature on treatment of venous thromboembolism (VTE) and
prevention of cardioembolic stroke with direct-acting oral anticoagulants (DOACs) in low …

Background: Direct oral anticoagulants (DOACs) present a favorable alternative to warfarin
based on the decreased burden of monitoring and fewer drug and food interactions …